earnings

This Diabetes Company's Q1 Earnings Reflect the Resiliency of Its Business Model
This Diabetes Company's Q1 Earnings Reflect the Resiliency of Its Business Model
Motley Fool
Insulet
diabetes
devices
insulin pumps
earnings
Flag link:
Here's Why Editas Could Beat Intellia to a CRISPR Therapy
Here's Why Editas Could Beat Intellia to a CRISPR Therapy
Motley Fool
gene editing
CRISPR
Editas Medicine
Intellia
earnings
Flag link:
Medtronic misses mark in Q4 as sales decline 26%
Medtronic misses mark in Q4 as sales decline 26%
Mass Device
Medtronic
devices
earnings
Flag link:
Is Amyris Finally Turning a Corner?
Is Amyris Finally Turning a Corner?
Motley Fool
Amyris
earnings
synthetic biology
Flag link:
Takeda posts surprise profit a year after Shire mega-merger
Takeda posts surprise profit a year after Shire mega-merger
Pharmaforum
Japan
Takeda
Shire
M&A
earnings
Flag link:
AMAG Pharma to Lay Off 140 Staffers as Part of Company Restructure
AMAG Pharma to Lay Off 140 Staffers as Part of Company Restructure
BioSpace
Amag Pharmaceuticals
earnings
layoffs
Flag link:
How GW Pharmaceuticals Hit a Home Run in Q1
How GW Pharmaceuticals Hit a Home Run in Q1
Motley Fool
GW Pharma
earnings
Epidiolex
Flag link:
What's Behind Mylan's Mixed Q1 Results
What's Behind Mylan's Mixed Q1 Results
Motley Fool
Mylan
Pfizer
Upjohn
M&A
Viatris
earnings
Flag link:
Endo International Fires on All Cylinders in Q1 Thanks to COVID-19 Impact
Endo International Fires on All Cylinders in Q1 Thanks to COVID-19 Impact
Motley Fool
Endo International
earnings
Flag link:
Neurocrine Biosciences Q1 Beats on Earnings, Revenue
Neurocrine Biosciences Q1 Beats on Earnings, Revenue
Motley Fool
Neurocrine
earnings
Flag link:
Here's Why Teva Pharmaceuticals Jumped Higher Today
Here's Why Teva Pharmaceuticals Jumped Higher Today
Motley Fool
Teva Pharmaceutical
earnings
Flag link:
3 Reasons Bristol Myers Squibb's Revenue Skyrocketed in Q1
3 Reasons Bristol Myers Squibb's Revenue Skyrocketed in Q1
Motley Fool
Bristol-Myers Squibb
earnings
Flag link:
Zoetis Beats Expectations in Q1 but Lowers Full-Year Outlook Due to COVID-19
Zoetis Beats Expectations in Q1 but Lowers Full-Year Outlook Due to COVID-19
Motley Fool
Zoetis
earnings
animal health
Flag link:
Why Jazz Pharmaceuticals Sang Off-Key in Q1
Why Jazz Pharmaceuticals Sang Off-Key in Q1
Motley Fool
Jazz Pharmaceuticals
earnings
Flag link:
Regeneron Says Its COVID-19 Combo Treatment Could Be Ready for People This Fall
Regeneron Says Its COVID-19 Combo Treatment Could Be Ready for People This Fall
Motley Fool
Regeneron
COVID-19
REGN-COV2
earnings
clinical trials
Flag link:
Why Mallinckrodt Stock Tumbled Today
Why Mallinckrodt Stock Tumbled Today
Motley Fool
Mallinckrodt
earnings
Flag link:
Why Incyte's Q1 Loss Isn't As Bad As It Looks
Why Incyte's Q1 Loss Isn't As Bad As It Looks
Motley Fool
Incyte
earnings
Flag link:
AbbVie Beats Q1 Estimates as U.S. Humira Sales Rise 13.7%
AbbVie Beats Q1 Estimates as U.S. Humira Sales Rise 13.7%
Motley Fool
AbbVie
earnings
Flag link:
3 Big Stories in Gilead Sciences' Q1 Results
3 Big Stories in Gilead Sciences' Q1 Results
Motley Fool
earnings
Gilead Sciences
remdesivir
COVID-19
Flag link:
Abiomed stock up amid Street-beating Q4 profits, news of Breethe acquisition
Abiomed stock up amid Street-beating Q4 profits, news of Breethe acquisition
Mass Device
Abiomed
devices
earnings
M&A
Breethe
ECMO
COVID-19
pandemic
Flag link:

Pages